Kyverna Therapeutics, Inc.
KYTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$36,787 | -$42,081 | -$44,635 | -$37,489 |
| Dep. & Amort. | $415 | $515 | $501 | $563 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $2,518 | $2,161 | $0 |
| Change in WC | -$8,853 | $8,227 | -$2,184 | $34 |
| Other Non-Cash | $1,904 | -$1,128 | -$758 | -$169 |
| Operating Cash Flow | -$43,321 | -$31,949 | -$44,915 | -$37,061 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$392 | -$4 | $0 | -$532 |
| Net Acquisitions | $70 | $0 | $0 | $0 |
| Inv. Purchases | -$72,821 | -$94,729 | -$81,122 | -$127,246 |
| Inv. Sales/Matur. | $95,700 | $124,100 | $84,590 | $157,000 |
| Other Inv. Act. | $0 | -$200 | $2,110 | $0 |
| Investing Cash Flow | $22,557 | $29,167 | $5,578 | $29,222 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$120 | -$262 | -$341 | -$247 |
| Stock Issued | $1,651 | -$336 | -$73 | $32 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$43 | -$51 | $0 | $0 |
| Financing Cash Flow | $1,488 | -$649 | -$414 | -$215 |
| Forex Effect | $0 | $0 | $0 | $12 |
| Net Chg. in Cash | -$19,276 | -$3,431 | -$39,751 | -$8,042 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $53,440 | $57,422 | $97,173 | $104,663 |
| End Cash | $34,164 | $53,991 | $57,422 | $96,621 |
| Free Cash Flow | -$43,713 | -$32,153 | -$44,915 | -$37,593 |